Patents by Inventor Philip Pye
Philip Pye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220098200Abstract: Described herein is the synthesis of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.Type: ApplicationFiled: February 17, 2021Publication date: March 31, 2022Inventors: Cyril Ben Haim, Wei Chen, Erick Goldman, Andras Horvath, Philip Pye, Mark S. Smyth, Erik J. Verner
-
Publication number: 20200347064Abstract: Described herein is the synthesis of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.Type: ApplicationFiled: December 4, 2019Publication date: November 5, 2020Inventors: Cyril Ben Haim, Wei Chen, Erick Goldman, Andras Horvath, Philip Pye, Mark S. Smyth, Erik J. Verner
-
Publication number: 20190367518Abstract: Described herein is the synthesis of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.Type: ApplicationFiled: December 18, 2018Publication date: December 5, 2019Inventors: Cyril Ben Haim, Wei Chen, Erick Goldman, Andras Horvath, Philip Pye, Mark S. Smyth, Erik J. Verner
-
Publication number: 20180009814Abstract: Described herein is the synthesis of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo [3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.Type: ApplicationFiled: January 14, 2016Publication date: January 11, 2018Applicants: Pharmacyclics LLC, Janssen Pharmaceutica NVInventors: Cyril Benhaim, Wei Chen, Erick Goldman, Andras Horvath, Philip Pye, Mark S. Smyth, Erik J. Verner
-
Publication number: 20150376193Abstract: Disclosed is a process for the preparation of the following compounds: where R1, R1a and R2a have the definitions in the description, as well as a process to prepare other intermediates that may be useful to synthesise downstream products, especially compounds that are useful as medicaments, for instance Bruton's tyrosine kinase (Btk) inhibitors such as ibrutinib. Also disclosed are other processes, other intermediates and compounds per se.Type: ApplicationFiled: September 9, 2015Publication date: December 31, 2015Inventors: Philip PYE, Cyril BEN HAIM, Matteo CONZA, Ioannis Nicolaos HOUPIS
-
Patent number: 9156847Abstract: Disclosed is a process for the preparation of the following compounds: where R1, R1a and R2a have the definitions in the description, as well as a process to prepare other intermediates that may be useful to synthesize downstream products, especially compounds that are useful as medicaments, for instance Bruton's tyrosine kinase (Btk) inhibitors such as ibrutinib. Also disclosed are other processes, other intermediates and compounds per se.Type: GrantFiled: March 11, 2014Date of Patent: October 13, 2015Assignee: Janssen Pharmaceutica NVInventors: Philip Pye, Cyril Ben Haim, Matteo Conza, Ioannis Nicolaos Houpis
-
Patent number: 9079900Abstract: Provided herein are methods to prepare Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein. The Heteroaryl compounds are useful for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.Type: GrantFiled: February 7, 2014Date of Patent: July 14, 2015Assignee: Signal Pharmaceuticals, LLCInventors: Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Gingsee Lee, Garrick Packard, Jingjing Zhao, Patrick Anthony Jokiel, Deborah Mortensen, Jennifer Riggs, Juan Antonio Gamboa, Marie Georges Beauchamps, Matthew Michael Kreilein, Mohit Atul Kothare, Sophie Perrin-Ninkovic, Philip Pye, William Wei-Hwa Leong, Jan Elsner, Anusuya Choudhury
-
Publication number: 20140275126Abstract: Disclosed is a process for the preparation of the following compounds: where R1, R1a and R2a have the definitions in the description, as well as a process to prepare other intermediates that may be useful to synthesise downstream products, especially compounds that are useful as medicaments, for instance Bruton's tyrosine kinase (Btk) inhibitors such as ibrutinib. Also disclosed are other processes, other intermediates and compounds per se.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Inventors: Philip PYE, Cyril BEN HAIM, Matteo CONZA, Ioannis Nicolaos HOUPIS
-
Publication number: 20140155593Abstract: Provided herein are methods to prepare Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein. The Heteroaryl compounds are useful for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Applicant: SIGNAL PHARMACEUTICALS, LLCInventors: Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Gingsee Lee, Garrick Packard, Jingjing Zhao, Patrick Anthony Jokiel, Deborah Mortensen, Jennifer Riggs, Juan Antonio Gamboa, Marie Georges Beauchamps, Matthew Michael Kreilein, Mohit Atul Kothare, Sophie Perrin-Ninkovic, Philip Pye, William Wei-Hwa Leong, Jan Elsner, Anusuya Choudhury
-
Patent number: 8686135Abstract: Provided herein are methods to prepare Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein. The Heteroaryl compounds are useful for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.Type: GrantFiled: April 30, 2013Date of Patent: April 1, 2014Assignee: Signal Pharmaceuticals, LLCInventors: Patrick Anthony Jokiel, Juan Antonio Gamboa, Philip Pye, William Wei-Hwa Leong, Anusuya Choudhury
-
Publication number: 20130245254Abstract: Provided herein are methods to prepare Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein. The Heteroaryl compounds are useful for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.Type: ApplicationFiled: April 30, 2013Publication date: September 19, 2013Applicant: SIGNAL PHARMACEUTICALS, LLCInventors: Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Gingsee Lee, Garrick Packard, Jingjing Zhao, Patrick Anthony Jokiel, Deborah Mortensen, Jennifer Riggs, Juan Antonio Gamboa, Marie Georges Beauchamps, Matthew Michael Kreilein, Mohit Atul Kothare, Sophie Perrin-Ninkovic, Philip Pye, William Wei-Hwa Leong, Jan Elsner, Anusuya Choudhury
-
Patent number: 8357798Abstract: Potassium salts of Compound A and methods for their preparation are disclosed, wherein Compound A is of formula: Compound A is an HIV integrase inhibitor useful for treating or prophylaxis of HIV infection, for delaying the onset of AIDS, and for treating or prophylaxis of AIDS.Type: GrantFiled: June 4, 2010Date of Patent: January 22, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Kevin M. Belyk, Henry G. Morrison, Philip Jones, Vincenzo Summa, V. Brett Cooper, Amar J. Mahajan, Daniel J. Kumke, Hsien-Hsin Tung, Lawrence Wai, Vanessa Pruzinsky, Philip Pye, Remy Angelaud, Danny Mancheno
-
Publication number: 20110137028Abstract: Provided herein are methods to prepare Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein. The Heteroaryl compounds are useful for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.Type: ApplicationFiled: October 25, 2010Publication date: June 9, 2011Inventors: Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Gingsee Lee, Garrick Packard, Jingjing Zhao, Patrick Anthony Jokiel, Deborah Mortensen, Jennifer Riggs, Juan Antonio Gamboa, Maria Georges Beauchamps, Matthew Michael Kreilein, Mohit Atul Kothare, Sophie Perrin-Ninkovic, Philip Pye, William Wei-Hwa Leong, Jan Elsner
-
Publication number: 20100249410Abstract: Potassium salts of Compound A and methods for their preparation are disclosed, wherein Compound A is of formula: Compound A is an HIV integrase inhibitor useful for treating or prophylaxis of HIV infection, for delaying the onset of AIDS, and for treating or prophylaxis of AIDS.Type: ApplicationFiled: June 4, 2010Publication date: September 30, 2010Inventors: Philip Pye, Remy Angelaud, Danny Mancheno
-
Publication number: 20070179196Abstract: Hydroxy (tetra- or hexa-)hydronaphthyridine dione compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: (I) wherein a, R,1?, R,2?, R,3?, R,4? and R,5? are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: March 9, 2005Publication date: August 2, 2007Inventors: Wei Han, Melissa Egbertson, John Wai, Linghang Zhuang, Rowena Ruzek, Debra Perlow, Richard Isaacs, Mark Cameron, Bruce Foster, Ulf Dolling, R. Hoermer, Vanessa Obligado, Lou Neilson, Boyoung Kim, Linda Payne, Matthew Morrissette, Peter Williams, Philip Pye, Remy Angelaud, Danny Mancheno, David Askin
-
Publication number: 20060122205Abstract: Potassium salts of Compound A and methods for their preparation are disclosed, wherein Compound A is of formula: Compound A is an HIV integrase inhibitor useful for treating or prophylaxis of HIV infection, for delaying the onset of AIDS, and for treating or prophylaxis of AIDS.Type: ApplicationFiled: December 2, 2005Publication date: June 8, 2006Inventors: Kevin Belyk, Henry Morrison, Philip Jones, Vincenzo Summa, V. Cooper, Amar Mahajan, Daniel Kumke, Hsien-Hsin Tung, Lawrence Wai, Vanessa Pruzinsky, Philip Pye, Remy Angelaud, Danny Mancheno
-
Patent number: 6043387Abstract: New chiral biphosphines, e.g., ##STR1## are useful as key components in catalysts for asymmetric reactions, providing desirably high enantiomeric excess (ee).Type: GrantFiled: February 3, 1999Date of Patent: March 28, 2000Assignee: Merck & Co., Inc.Inventors: Philip Pye, Ralph P. Volante, Kai Rossen
-
Patent number: 5874629Abstract: New chiral biphosphines, e.g., ##STR1## are useful as key components in catalysts for asymmetric reactions, providing desirably high enantiomeric excess (ee).Type: GrantFiled: June 9, 1997Date of Patent: February 23, 1999Assignee: Merck & Co., Inc.Inventors: Philip Pye, Kai Rossen, Ralph P. Volante
-
Patent number: 5709362Abstract: The present invention relates to semi-trailer support legs. In order to avoid damage to trailer support legs by failure to raise the legs when the trailer is coupled to a towing unit for movement, the present invention provides a pivotal foot at the end of the support leg and an actuator for controlling pivotal movement of the foot between a raised position providing sufficient clearance for normal operation and a deployed position for supporting the trailer on uncoupling of the towing unit. More particularly raising and lowering of the pivotal foot is controlled automatically on coupling and uncoupling respectively of the towing unit and trailer.A particularly convenient arrangement results where actuation of the foot is responsive to the connection and disconnection of a control line between the towing and trailer units. More particularly still, the control line is the emergency brake line which would be connected as a matter of course. The actuator is supplied from a branch off said emergency brake line.Type: GrantFiled: May 12, 1995Date of Patent: January 20, 1998Assignee: Pandoro LimitedInventors: Martin Robert Clarke, Philip Pye, Norman Zoltan Wignall